Consensus Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
42.12 ^USD	-0.40%		-1.98%	+18.38%

Apr. 17	Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	MT
Mar. 26	Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Crinetics Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

fe070af79.iL3IvHc21LTX9tgwb2IIQNK88YEBuGUjjYwtHG2mKJw.weqp5iIFttvjpIhaJjheJoPfgux79BBR-rlfaQPhcK3M5fnzHF2E-6WQkQ~31be217b959214e183dcbf351dec6ad0

Analyst Recommendations on Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	Apr. 17	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $664,763, According to a Recent SEC Filing	Mar. 22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $2,648,150, According to a Recent SEC Filing	Mar. 22	MT
Crinetics Pharmaceuticals Insider Sold Shares Worth $449,793, According to a Recent SEC Filing	Mar. 21	MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $80 From $60, Maintains Market Outperform Rating	Mar. 20	MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $55 From $54, Maintains Outperform Rating	Mar. 20	MT
JonesTrading Raises Crinetics Pharmaceuticals' Price Target to $56 From $52, Maintains Buy Rating	Mar. 20	MT
HC Wainwright Raises Crinetics Pharmaceuticals Price Target to $60 From $50, Maintains Buy Rating	Mar. 20	MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $54 From $48, Maintains Outperform Rating	Mar. 13	MT
HC Wainwright Adjusts Crinetics Pharmaceuticals Price Target to $50 From $42, Maintains Buy Rating	Mar. 08	MT
Citigroup Initiates Crinetics Pharmaceuticals With Buy Rating, $68 Price Target	Mar. 06	MT
Cantor Fitzgerald Adjusts Price Target on Crinetics Pharmaceuticals to $65 From $50, Maintains Overweight Rating	Mar. 04	MT
Oppenheimer Raises Crinetics Pharmaceuticals Price Target to $48 From $46, Maintains Outperform Rating	Feb. 29	MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $52 From $45, Maintains Outperform Rating	Feb. 29	MT
Investors got more clues that rate cuts are imminent	Dec. 19
Evercore ISI Adjusts Price Target on Crinetics Pharmaceuticals to $48 From $41, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Adjusts Crinetics Pharmaceuticals Price Target to $46 From $40, Maintains Outperform Rating	23-09-11	MT
Baird Adjusts Crinetics Pharmaceuticals Price Target to $45 From $43, Maintains Outperform Rating	23-09-11	MT
Oppenheimer Initiates Coverage on Crinetics Pharmaceuticals With Outperform Rating, $40 Price Target	23-08-31	MT
HC Wainwright Trims Price Target on Crinetics Pharmaceuticals to $33 From $35, Maintains Buy Rating	23-08-09	MT
JMP Securities Adjusts Crinetics Pharmaceuticals Price Target to $43 From $41, Maintains Market Outperform Rating	23-05-05	MT
Piper Sandler Initiates Coverage on Crinetics Pharmaceuticals With Overweight Rating, $56 Price Target	23-04-24	MT
Baird Initiates Crinetics Pharmaceuticals at Outperform With $48 Price Target	23-03-30	MT
Lifesci Capital Initiates Crinetics Pharmaceuticals at Outperform, $57 Price Target	23-03-27	MT
JMP Securities Adjusts Price Target on Crinetics Pharmaceuticals to $41 From $50, Keeps Market Outperform Rating	23-03-01	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42.12 USD

Average target price

56.86 USD

Spread / Average Target

+34.99%

High Price Target

80 USD

Spread / Highest target

+89.93%

Low Price Target

40 USD

Spread / Lowest Target

-5.03%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Crinetics Pharmaceuticals, Inc.

HC Wainwright
JonesTrading Institutional Services
Oppenheimer
JMP Securities
Citigroup
Cantor Fitzgerald
Baird
Evercore ISI
Piper Sandler
LifeSci Capital
SVB Securities LLC
JPMorgan Chase

Ratings for Crinetics Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar